Can GLP-1 Drugs Treat Addiction?

Join Dr. Ben Synth as he explores how GLP-1 diabetes drugs are showing astonishing potential to quiet cravings for alcohol, opioids, nicotine, and gambling. Through groundbreaking veteran studies and cutting-edge neuroscience, discover whether we're witnessing a revolution in addiction medicine or chasing another false promise. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Ben Synth examines whether GLP-1 diabetes drugs represent a breakthrough in addiction treatment or premature hope. We explore compelling veterans study data showing dramatic reductions in overdoses and substance use deaths, alongside expert insights from Stanford's Anna Lembke and Brown's Carolina Haass-Koffler. The episode discusses promising mechanisms, conflicting preclinical findings, and ongoing clinical trials. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Ben Synth explores a BMJ study revealing GLP-1 drugs showed remarkable reductions in substance use disorders among U.S. veterans—including 50% fewer addiction-related deaths and 40% fewer overdoses. We examine the extraordinary data, biological mechanisms, critical limitations of observational research, and why these findings demand urgent investigation despite incomplete clinical trial evidence. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Ben Synth explores how GLP-1 drugs like Ozempic and Wegovy are unexpectedly quieting addiction cravings—not just for food, but for alcohol, nicotine, and opioids. The episode digs into the neuroscience of reward circuits, the gut-brain axis, and why a diabetes medication might hold promise for treating substance use disorders by targeting shared craving architecture. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.